Doug Smith, MD, John Hopkins Medicine

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.